1
|
Kittai AS, Hang Y, Bhat SA, Clark A, Grever M, Rhodes JM, Roberts M, Rogers KA, Teschemaker A, Munoz-Sagastibelza M, Woyach JA, Barrientos JC. Racial disparities in chronic lymphocytic leukemia/small lymphocytic lymphoma accounting for small molecule inhibitors: A real-world cohort analysis. Am J Hematol 2024; 99:780-784. [PMID: 38357757 DOI: 10.1002/ajh.27241] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/26/2023] [Revised: 01/16/2024] [Accepted: 01/19/2024] [Indexed: 02/16/2024]
Abstract
Kaplan-Meier curve depicting overall survival from CLL treatment start by race. For patients with CLL, no overall survival difference was observed between races in this real-world US database.
Collapse
Affiliation(s)
- Adam S Kittai
- Division of Hematology, The Ohio State University, Columbus, Ohio, USA
| | - Ying Hang
- Division of Hematology, The Ohio State University, Columbus, Ohio, USA
| | - Seema A Bhat
- Division of Hematology, The Ohio State University, Columbus, Ohio, USA
| | - Abi Clark
- US Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA
| | - Michael Grever
- Division of Hematology, The Ohio State University, Columbus, Ohio, USA
| | - Joanna M Rhodes
- Rutgers Cancer Institute of New Jersey, New Brunswick, New Jersey, USA
| | - Melyssa Roberts
- US Medical Affairs, AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA
| | - Kerry A Rogers
- Division of Hematology, The Ohio State University, Columbus, Ohio, USA
| | - Anna Teschemaker
- Global Evidence Generation, AstraZeneca Pharmaceuticals, Gaithersburg, Maryland, USA
| | | | - Jennifer A Woyach
- Division of Hematology, The Ohio State University, Columbus, Ohio, USA
| | - Jacqueline C Barrientos
- Zucker School of Medicine at Hofstra/Northwell, Lake Success, New York, USA
- Mount Sinai Comprehensive Cancer Center, Miami, Florida, USA
| |
Collapse
|
2
|
Teschemaker A, Hakre S, Tse J, Shaikh NF, Gu Y, Near A. HSR23-119: Real-World Duration of Venetoclax Treatment for Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia (CLL/SLL). J Natl Compr Canc Netw 2023. [DOI: 10.6004/jnccn.2022.7221] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
3
|
Parasuraman S, Thiel E, Park J, Teschemaker A. Productivity loss outcomes and costs among patients with cholangiocarcinoma in the United States: an economic evaluation. J Med Econ 2023; 26:454-462. [PMID: 36883994 DOI: 10.1080/13696998.2023.2187604] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/09/2023]
Abstract
BACKGROUND Cholangiocarcinoma (CCA) is associated with poor prognosis. Healthcare-related management likely presents a substantial economic burden associated with time away from work in patients with CCA. OBJECTIVES To assess productivity loss, associated indirect costs, and all-cause healthcare resource utilization and costs owing to workplace absenteeism, short-term disability, and long-term disability in CCA patients with work absence and disability benefits eligibility in the United States. METHODS US retrospective claims data from Merative MarketScan Commercial and Health and Productivity Management Databases. Eligible patients were adults with ≥1 non-diagnostic medical claim for CCA in the index period (1 January 2011-31 December 2019) and had ≥6 months of continuous medical and pharmacy benefit enrolment before and ≥1 month of follow-up and full-time employee work absence and disability benefits eligibility after the index date. Outcomes were assessed in patients with CCA, intrahepatic CCA (iCCA), and extrahepatic CCA (eCCA) in absenteeism, short-term disability, and long-term disability cohorts (measured per patient per month [PPPM] for a month of 21 workdays), with costs standardized to 2019 USD. RESULTS One thousand and sixty-five patients with CCA were included (iCCA: n = 624 [58.6%]; eCCA: n = 380 [35.7%]). The mean age was 51.9-53.9 years across cohorts. In patients with iCCA and eCCA, respectively, the number of mean all-cause days absent PPPM for illness was 6.0 and 4.3, and 12.9 and 6.6% had ≥1 CCA-related short-term disability claim. Median indirect costs PPPM owing to absenteeism, short-term disability, and long-term disability, respectively, in patients with iCCA were $622, $635, and $690, and $304, $589, and $465 in patients with eCCA. Patients with iCCA vs. eCCA had higher inpatient, outpatient medical, outpatient pharmacy, and all-cause healthcare costs PPPM. CONCLUSIONS Patients with CCA had high productivity losses, indirect costs, and medical costs. Outpatient services costs contributed greatly to the higher healthcare expenditure observed in patients with iCCA vs. eCCA.
Collapse
|
4
|
Javle M, Lee S, Azad NS, Borad MJ, Kate Kelley R, Sivaraman S, Teschemaker A, Chopra I, Janjan N, Parasuraman S, Bekaii-Saab TS. Temporal Changes in Cholangiocarcinoma Incidence and Mortality in the United States from 2001 to 2017. Oncologist 2022; 27:874-883. [PMID: 35972334 PMCID: PMC9526482 DOI: 10.1093/oncolo/oyac150] [Citation(s) in RCA: 21] [Impact Index Per Article: 10.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2021] [Accepted: 06/02/2022] [Indexed: 11/29/2022] Open
Abstract
Background Previous studies report increasing cholangiocarcinoma (CCA) incidence up to 2015. This contemporary retrospective analysis of CCA incidence and mortality in the US from 2001-2017 assessed whether CCA incidence continued to increase beyond 2015. Patients and Methods Patients (≥18 years) with CCA were identified in the National Cancer Institute Surveillance, Epidemiology, and End Results 18 cancer registry (International Classification of Disease for Oncology [ICD-O]-3 codes: intrahepatic [iCCA], C221; extrahepatic [eCCA], C240, C241, C249). Cancer of unknown primary (CUP) cases were identified (ICD-O-3: C809; 8140/2, 8140/3, 8141/3, 8143/3, 8147/3) because of potential misclassification as iCCA. Results Forty-thousand-and-thirty CCA cases (iCCA, n=13,174; eCCA, n=26,821; iCCA and eCCA, n=35) and 32,980 CUP cases were analyzed. From 2001-2017, CCA, iCCA, and eCCA incidence (per 100 000 person-years) increased 43.8% (3.08 to 4.43), 148.8% (0.80 to 1.99), and 7.5% (2.28 to 2.45), respectively. In contrast, CUP incidence decreased 54.4% (4.65 to 2.12). CCA incidence increased with age, with greatest increase among younger patients (18-44 years, 81.0%). Median overall survival from diagnosis was 8, 6, 9, and 2 months for CCA, iCCA, eCCA, and CUP. From 2001-2016, annual mortality rate declined for iCCA (57.1% to 41.2%) and generally remained stable for eCCA (40.9% to 37.0%) and for CUP (64.3% to 68.6%). Conclusions CCA incidence continued to increase from 2001-2017, with greater increase in iCCA versus eCCA, whereas CUP incidence decreased. The divergent CUP versus iCCA incidence trends, with overall greater absolute change in iCCA incidence, provide evidence for a true increase in iCCA incidence that may not be wholly attributable to CUP reclassification.
Collapse
Affiliation(s)
- Milind Javle
- Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Sunyoung Lee
- Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - Nilofer S Azad
- Gastrointestinal Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, USA
| | | | - Robin Kate Kelley
- University of California at San Francisco, Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, USA
| | | | | | | | | | | | | |
Collapse
|
5
|
Teschemaker A, Thiel E, Park J, Parasuraman S. Productivity loss outcomes and indirect costs among patients (Pts) with cholangiocarcinoma (CCA). J Clin Oncol 2022. [DOI: 10.1200/jco.2022.40.4_suppl.392] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
392 Background: CCA pts, often diagnosed at older age with advanced disease, face poor prognoses and economic burden. Despite increasing CCA incidence in working age pts, little is known on financial impact on working pts. This study describes the impact of CCA on productivity loss and indirect costs due to workplace absence, short-term disability (STD), and long-term disability (LTD). Methods: Retrospective claims data from IBM MarketScan Commercial and Health and Productivity Management (HPM) databases between 7/1/2010 to 12/31/2019 were used. Eligible pts were ≥18 years, had ≥1 non-ruleout claim for CCA ( ICD-9/ -10: intrahepatic [iCCA]: 155.1/C221; extrahepatic [eCCA]: 156.1, 156.9/C240, C249) in the index period (1/1/2011 – 12/31/2019), and had ≥6 months of continuous medical and pharmacy benefit enrollment before and ≥1 month of follow-up and full-time employee eligibility after index date. Productivity loss as absenteeism, STD, and LTD among iCCA and eCCA was reported per pt per month (PPPM) for a work month of 21 days. Absenteeism was defined as absence days for illness; STD and LTD were defined as days on disability leave. Indirect cost was estimated using wage equivalent to median hourly wage rate and salary replacement rate of 70% from US Bureau of Labor and Statistics. Results: A total of 1065 CCA pts (iCCA, n=624 [58.6%]; eCCA, n=380 [35.7%]) were identified. The number of productivity benefit–eligible pts for analysis in absenteeism, STD, and LTD were 107, 617, and 549, respectively. Across cohorts, mean age ranged from 51.9 to 53.9 years; >60% were men. Mean (SD) follow-up time (days) was 725.0 (730.4) for absenteeism, 639.7 (587.0) for STD, and 614.4 (583.2) for LTD. The most notable comorbidities across cohorts were moderate/severe liver disease (58–63%) and pain (67–71%). Among pts with productivity claims, more CCA-related absences and higher related indirect costs were observed in iCCA than eCCA pts. The trend in all-cause disability outcomes of STD, LTD, and related costs was less clear between iCCA and eCCA pts; however, medical costs were higher in iCCA pts. Conclusions: CCA pts had high productivity loss and indirect costs, which is pt costs due to days missed from work in addition to medical costs; iCCA pts incurred substantially more absences, related indirect costs, and medical costs than eCCA pts.[Table: see text]
Collapse
|
6
|
Parasuraman S, Lal L, Bunner S, Paranagama D, Teschemaker A, Snodgrass S, Sivaraman S. HSR20-104: Treatment Patterns and Time Trends for Intrahepatic Cholangiocarcinoma (iCCA) Patients: A Real-World Retrospective Claims Study. J Natl Compr Canc Netw 2020. [DOI: 10.6004/jnccn.2019.7472] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
7
|
Neslusan C, Teschemaker A, Willis M, Johansen P, Vo L. Cost-Effectiveness Analysis of Canagliflozin 300 mg Versus Dapagliflozin 10 mg Added to Metformin in Patients with Type 2 Diabetes in the United States. Diabetes Ther 2018; 9:565-581. [PMID: 29411292 PMCID: PMC6104269 DOI: 10.1007/s13300-018-0371-y] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/05/2017] [Indexed: 12/17/2022] Open
Abstract
INTRODUCTION Agents that inhibit sodium glucose co-transporter 2 (SGLT2), including canagliflozin and dapagliflozin, are approved in the United States for the treatment of adults with type 2 diabetes mellitus (T2DM). SGLT2 inhibition lowers blood glucose by increasing urinary glucose excretion, which leads to a mild osmotic diuresis and a net loss of calories that are associated with reductions in body weight and blood pressure. This analysis evaluated the cost-effectiveness of canagliflozin 300 mg versus dapagliflozin 10 mg in patients with T2DM inadequately controlled with metformin in the United States. METHODS A 30-year cost-effectiveness analysis was performed using the validated Economic and Health Outcomes Model of T2DM (ECHO-T2DM) from the perspective of the third-party health care system in the United States. Patient demographics, biomarker values, and treatment effects for the ECHO-T2DM model were sourced primarily from a network meta-analysis (NMA) that included studies of canagliflozin and dapagliflozin in patients with T2DM on background metformin. Costs were derived from sources specific to the United States. Outcomes and costs were discounted at 3%. Sensitivity analyses that varied key model parameters were conducted. RESULTS Canagliflozin 300 mg dominated dapagliflozin 10 mg as an add-on to metformin over 30 years, with an estimated cost offset of $13,991 and a quality-adjusted life-year gain of 0.08 versus dapagliflozin 10 mg. Results were driven by the better HbA1c lowering achieved with canagliflozin, which translated to less need for insulin rescue therapy. Findings from sensitivity analyses were consistent with the base case. CONCLUSION These results suggest that canagliflozin 300 mg is likely to provide better health outcomes at a lower overall cost than dapagliflozin 10 mg in patients with T2DM inadequately controlled with metformin from the perspective of the United States health care system. FUNDING Janssen Scientific Affairs, LLC and Janssen Global Services, LLC.
Collapse
Affiliation(s)
| | | | - Michael Willis
- The Swedish Institute for Health Economics, Lund, Sweden
| | | | - Lien Vo
- Janssen Scientific Affairs, LLC, Titusville, NJ, USA
| |
Collapse
|
8
|
Sabapathy S, Neslusan C, Yoong K, Teschemaker A, Johansen P, Willis M. Cost-effectiveness of Canagliflozin versus Sitagliptin When Added to Metformin and Sulfonylurea in Type 2 Diabetes in Canada. J Popul Ther Clin Pharmacol 2016; 23:e151-e168. [PMID: 27463416] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/06/2023]
Abstract
BackgroundCanagliflozin, an agent that inhibits sodium glucose co-transporter 2, is approved as add-on to metformin plus sulfonylurea for the treatment of type 2 diabetes in Canada. Canagliflozin offers greater glycemic control, as well as important additional benefits such as weight loss and blood pressure reductions, versus dipeptidyl peptidase-4 inhibitors such as sitagliptin. ObjectiveThis analysis evaluated the cost-effectiveness of canagliflozin 300 mg and canagliflozin 100 mg versus sitagliptin 100 mg in patients with type 2 diabetes inadequately controlled on metformin plus sulfonylurea from the perspective of the Canadian Agency for Drugs and Technologies in Health. MethodsA 40-year cost-effectiveness analysis was performed using the validated Economic and Health Outcomes Model of Type 2 Diabetes Mellitus (ECHO-T2DM). Patient characteristics, treatment effects, and rates of hypoglycemia and adverse events were sourced from the canagliflozin clinical program. Canada-specific costs and utilities were applied. Sensitivity analyses were conducted using alternative values for key model inputs. ResultsBoth canagliflozin 300 and 100 mg dominated sitagliptin 100 mg over 40 years, providing quality-adjusted life-year gains of 0.31 and 0.28, and cost offsets of $2,217 and $2,560, respectively. Both canagliflozin doses dominated sitagliptin in each of the sensitivity analyses. ConclusionsSimulation results suggested that canagliflozin 300 and 100 mg provided better health outcomes and lower costs than sitagliptin 100 mg as a third-line therapy added-on to metformin and sulfonylurea in patients with type 2 diabetes in Canada.
Collapse
|
9
|
Neslusan C, Teschemaker A, Johansen P, Willis M, Valencia-Mendoza A, Puig A. Cost-Effectiveness of Canagliflozin versus Sitagliptin as Add-on to Metformin in Patients with Type 2 Diabetes Mellitus in Mexico. Value Health Reg Issues 2015; 8:8-19. [PMID: 29698175 DOI: 10.1016/j.vhri.2015.01.002] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/31/2014] [Revised: 10/24/2014] [Accepted: 01/06/2015] [Indexed: 11/17/2022]
Abstract
OBJECTIVE To assess the cost-effectiveness of canagliflozin versus sitagliptin for the treatment of type 2 diabetes mellitus (T2DM) as an add-on to metformin in Mexico. METHODS A validated model (Economic and Health Outcomes [ECHO]-T2DM) was used to estimate the cost-effectiveness of canagliflozin 300 or 100 mg versus sitagliptin 100 mg in patients with T2DM inadequately controlled on metformin monotherapy. Data from a head-to-head, phase III clinical trial, including patients' baseline demographic characteristics, biomarker values, and treatment effects, were used to simulate outcomes and resource use over 20 years from the perspective of the Mexican health care system. Costs of complications and adverse events were tailored to the Mexican setting and discounted at 5%. Cost-effectiveness was assessed using willingness-to-pay thresholds equivalent to 1 times the gross domestic product per capita (locally perceived to be "very cost-effective") and 3 times the gross domestic product per capita (locally perceived to be "cost-effective") on the basis of recommendations of the Mexican government and the World Health Organization. RESULTS Owing primarily to better glycated hemoglobin (HbA1c), body weight, and systolic blood pressure values, canagliflozin 300 and 100 mg were associated with an incremental benefit of 0.16 and 0.06 quality-adjusted life-years (QALYs) versus sitagliptin 100 mg, respectively, over 20 years. The mean differences in cost for canagliflozin 300 and 100 mg versus sitagliptin 100 mg were Mexican pesos (MXP) 1797 (US $134) and MXP 7262 (US $540), respectively, resulting in a cost per QALY gained of MXP 11,210 (US $834) and MXP 128,883 (US $9590), respectively. Both of these cost-effectiveness ratios are below the very cost-effective willingness-to-pay threshold in Mexico. The general finding that canagliflozin is cost-effective versus sitagliptin in Mexico was supported by sensitivity analyses. CONCLUSION In Mexico, both doses of canagliflozin are likely to be cost-effective versus sitagliptin in patients with T2DM who have inadequate glucose control on metformin, primarily because of better biomarker control and higher QALYs.
Collapse
Affiliation(s)
| | | | | | - Michael Willis
- The Swedish Institute for Health Economics, Lund, Sweden
| | | | - Andrea Puig
- Johnson and Johnson International, New Brunswick, NJ, USA
| |
Collapse
|
10
|
Teschemaker A, Lee E, Xue Z, Wutoh AK. Osteoporosis pharmacotherapy and counseling services in US ambulatory care clinics: Opportunities for multidisciplinary interventions. ACTA ACUST UNITED AC 2008; 6:240-8. [DOI: 10.1016/j.amjopharm.2008.12.002] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/29/2008] [Indexed: 10/21/2022]
|